What one share of Kyverna Therapeutics holds
We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy.
Kyverna Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.89 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.01 |
| Cash and investments | $3.24 |
| Debt | $0.41 |
| Book value | $2.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$89.61 | $0.92 | −$78.73 | — | −$10.51 |
| 2024 | — | −$3.33 | $0.06 | −$3.04 | — | $6.17 |
| 2025 | — | −$3.64 | $0.00 | −$3.47 | — | $3.85 |
Common questions about Kyverna Therapeutics
How much does one share of Kyverna Therapeutics earn?
Over the last 12 months, Kyverna Therapeutics lost $2.89 for each share.
Does Kyverna Therapeutics pay a dividend?
Kyverna Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Kyverna Therapeutics’s book value per share?
Kyverna Therapeutics’s book value is $2.69 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Kyverna Therapeutics have?
Each share of Kyverna Therapeutics has $3.24 of cash and investments and $0.41 of debt, as of June 30, 2026.
What is Kyverna Therapeutics’s free cash flow per share?
−$3.01 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.